Spots Global Cancer Trial Database for Safety and Efficacy of Durvalumab Combined to Neoadjuvant Chemotherapy in Localized Luminal B HER2(-) and Triple Negative Breast Cancer.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Safety and Efficacy of Durvalumab Combined to Neoadjuvant Chemotherapy in Localized Luminal B HER2(-) and Triple Negative Breast Cancer.
Official Title: A Phase IB/II Study of Durvalumab (MEDI4736) Combined With Dose-dense EC in a Neoadjuvant Setting for Patients With Locally Advanced Luminal B HER2(-) or Triple Negative Breast Cancers.
Study ID: NCT03356860
Study Description
Brief Summary: The study has a phase Ib and a phase II part. * The phase Ib aims to evaluate the safety and tolerability of durvalumab in combination with a dose- dense EC regimen in a neoadjuvant setting for early breast cancer. * The phase II aims to explore the efficacy of durvalumab in combination with a dose-dense EC regimen in a neoadjuvant setting for early breast cancer.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Grand Hôpital de Charleroi, Charleroi, Hainaut, Belgium
CHU UCL Namur - Sainte-Elisabeth, Namur, Région Wallonne, Belgium
CHU UCL Namur - Site Godinne, Yvoir, Région Wallonne, Belgium
Cliniques universitaires St Luc, Brussels, , Belgium
Contact Details
Name: Javier Carrasco, MD, PhD
Affiliation: GHdC
Role: PRINCIPAL_INVESTIGATOR
Name: Jean-Luc Canon, MD
Affiliation: GHdC
Role: PRINCIPAL_INVESTIGATOR
Name: François Duhoux, MD, PhD
Affiliation: Cliniques universitaires Saint-Luc (UCL)
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
